

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**TRANSPARENT PLASTIC BOX CONTAINING 5 OR 10 X 1 DOSE**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Versican Plus BbPi IN nasal drops, lyophilisate and solvent for suspension.

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each dose of 0.5 ml contains:

**Active substances:**

<i>Bordetella bronchiseptica</i>	10 <sup>8.0</sup> – 10 <sup>9.8</sup> CFU
Canine parainfluenza Type 2 virus	10 <sup>3.5</sup> – 10 <sup>5.8</sup> CCID <sub>50</sub>

**3. PACKAGE SIZE**

5 x 1 dose  
10 x 1 dose

**4. TARGET SPECIES**

Dogs.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Nasal use.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}  
Once reconstituted use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated.  
Do not freeze.  
Protect from light.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Zoetis UK Limited

**14. MARKETING AUTHORISATION NUMBERS**

Vm 42058/3032

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**VIAL (1 DOSE LYOPHILISATE)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Versican Plus BbPi IN



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

BbPi

1 dose

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once reconstituted use immediately.

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**VIAL (0.5 ML SOLVENT)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Versican Plus BbPi IN



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

*Aqua ad iniectabilia*

0.5 ml

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

## **B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

Versican Plus BbPi IN nasal drops, lyophilisate and solvent for suspension for dogs

### 2. Composition

Each dose of 0.5 ml contains:

#### Active substances:

Live attenuated *Bordetella bronchiseptica* strain MSLB 3096  $10^{8.0} - 10^{9.8}$  CFU\*

Live attenuated Canine parainfluenza Type 2 virus, strain CPIV-2 Bio 15

$10^{3.5} - 10^{5.8}$  CCID<sub>50</sub>\*\*

\*CFU: Colony forming unit.

\*\*CCID<sub>50</sub>: Cell culture infectious dose 50%.

#### Solvent:

Water for injections (*Aqua iniectionabilis*)

0.5 ml.

The visual appearance is as follows:

Lyophilisate: spongy matter of whitish to yellowish colour.

Solvent: clear colourless liquid.

### 3. Target species

Dogs.

### 4. Indications for use

Active immunisation of dogs from 3 weeks of age:

- to reduce clinical signs and bacterial excretion after infection with *Bordetella bronchiseptica* and
- to reduce clinical signs and viral excretion after infection with canine parainfluenza virus.

Onset of immunity: 3 days after primary vaccination for *Bordetella bronchiseptica*.  
7 days after primary vaccination for canine parainfluenza virus.

Duration of immunity: 1 year.

### 5. Contraindications

None.



## **6. Special warnings**

### Special warnings:

Vaccinate healthy animals only.

This veterinary medicinal product contains a live attenuated bacterial strain and antibiotics may interfere with the veterinary medicinal product's efficacy. Therefore, vaccinated dogs should not receive antibiotic treatment. If antibiotics are used within one week after vaccination, vaccination against *Bordetella bronchiseptica* should be repeated e.g. with a Bb monovalent vaccine (if available) after completion of the antibiotic treatment.

### Special precautions for safe use in the target species:

After vaccination dogs may excrete the vaccine strain *Bordetella bronchiseptica* for up to 11 weeks after vaccination and the vaccine strain canine parainfluenza virus for 8 days. Unvaccinated dogs can manifest mild clinical signs such as sneezing and nasal and ocular discharge after contact with vaccinated dogs.

The transmission of vaccine strains to cats, pigs and rodents could not be demonstrated. However, as the possibility of transmission to non-target species cannot be rejected, it is recommended to keep non-vaccinated animals out of close contact with vaccinated dogs for at least 4 weeks.

Safe handling and proper administration of the veterinary medicinal product and disposal of used material contribute to eliminating the risk of spreading the vaccine antigens in the veterinary workplace.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Hands and tools should be disinfected after use.

In case of accidental self-administration during dilution of the veterinary medicinal product or inhalation of the veterinary medicinal product in the form of aerosol during administration into the nostril of a dog, seek medical advice immediately and show the package leaflet or the label to the physician.

Although the risk that immunocompromised people are infected with *Bordetella bronchiseptica* is extremely low, it should be borne in mind that dogs can excrete the bacteria for up to several weeks after vaccination. Immunocompromised persons are advised to avoid contact with the veterinary medicinal product and vaccinated dogs during excretion.

### Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Therefore, the use is not recommended during pregnancy and lactation.

### Interaction with other medicinal products and other forms of interaction:

This veterinary medicinal product has been shown safe in dogs from 8 weeks of age when given at the same time as vaccines of the Versican Plus/Biocan Novel and Vanguard ranges containing live canine parvovirus, adenovirus, distemper virus, parainfluenza virus as well as inactivated *Leptospira* and rabies virus. Mild (< 1 °C), transient increases in temperature were very commonly observed following co-administration of these vaccines.

Efficacy after concurrent use has not been tested. Therefore, while safety of concurrent use has been demonstrated, the veterinarian should take this into account when deciding to administer the veterinary medicinal products at the same time.

Although proven safe it should not be necessary to give a parainfluenza vaccine twice by two different routes, therefore the veterinarian should consider vaccination options based on local availability of core vaccines without parainfluenza and monovalent Bordetella vaccines.

No information is available on the safety and efficacy of this veterinary medicinal product when used with any other veterinary medicinal product except the products mentioned above. A decision to use this veterinary medicinal product before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

No adverse events other than those mentioned in section “Adverse events” were observed after administration of a 10-fold overdose of the veterinary medicinal product.

Major incompatibilities:

Do not mix with any other veterinary medicinal product, except solvent supplied for use with the veterinary medicinal product.

## **7. Adverse events**

Dogs:

Very common (>1 animal / 10 animals treated):
Nasal discharge <sup>1</sup>
Common (1 to 10 animals / 100 animals treated):
Ocular discharge <sup>1</sup>
Cough <sup>2</sup>
Depression <sup>1</sup>
Uncommon (1 to 10 animals / 1,000 animals treated):
Sneezing <sup>1</sup>

<sup>1</sup>Mild and generally subside without treatment within 1 to 3 days.

<sup>2</sup>Mild to moderate and observed in vaccinated dogs within 48 hours to one week after vaccination.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>  
e-mail: [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

## **8. Dosage for each species, routes and method of administration**

Nasal use.

### Primary vaccination scheme:

A single dose from 3 weeks of age.

### Re-vaccination scheme:

A single dose to be given annually.

## **9. Advice on correct administration**

Aseptically reconstitute the lyophilisate with the solvent. Shake well after reconstitution. Withdraw the liquid with the syringe, remove the needle and administer directly from the tip of the syringe into one nostril. Alternatively, an intranasal applicator (available separately) can be attached to the syringe and the dose then administered into one nostril. The veterinary medicinal product should then be used immediately.

The head of the dog should be held with the nose pointing upwards. Administer one dose (0.5 ml) of the reconstituted veterinary medicinal product into one nostril.

Appearance of the reconstituted vaccine: whitish to yellowish colour with light opalescence.

## **10. Withdrawal periods**

Not applicable.

## **11. Special storage precautions**

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after reconstitution according to directions: use immediately.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon <or pharmacist> how to dispose of medicines no longer required.

### **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

### **14. Marketing authorisation numbers and pack sizes**

Vm 42058/3032

Transparent plastic box containing 5 vials of lyophilisate (1 dose) and 5 vials of solvent (0.5 ml).

Transparent plastic box containing 10 vials of lyophilisate (1 dose) and 10 vials of solvent (0.5 ml).

Not all pack sizes may be marketed.

Applicators are packed separately and can be distributed together with the veterinary medicinal product on request.

### **15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

### **16. Contact details**

Marketing authorisation holder and contact details to report suspected adverse reactions:

Zoetis UK Limited  
1st Floor, Birchwood Building  
Springfield Drive  
Leatherhead  
Surrey  
KT22 7LP

Manufacturer responsible for batch release:

Bioveta a.s.  
Komenskeho 212/12  
683 23 Ivanovice Na Hane  
Czechia

<Local representatives> and contact details to report suspected adverse reactions>:>  
*To be completed nationally (if applicable)*

**17. Other information**

Live vaccine stimulating active immunity against *Bordetella bronchiseptica* and canine parainfluenza virus in dogs.

*Gavin Hall*  
Approved: 20 September 2024